This April, NYU Langone Health’s Perlmutter Cancer Center researchers and physicians joined colleagues from around the world at the American Association for Cancer Research annual meeting in Orlando, Florida. View full conference information and abstract titles.
Below are notable sessions featuring our faculty and fellows this year.
Saturday, April 15
Session
The lymph-borne melanoma proteome conditions lymph nodes for metastasis
Presenter: Amanda W. Lund, PhD
Time: 8:30–8:50 am
Session
Cancer cell states and plasticity in drug-induced adaptation
Presenter: Gustavo Starvaggi França, PhD
Time: 8:30–8:50 am
Plenary Session
PL01 – Beating KRAS: A 30-Year Overnight Sensation
Chair: Dafna Bar-Sagi, PhD
Time: 4:15–6:15 pm
Sunday, April 16
Session
A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial
Presenter: Jeffrey S. Weber, MD, PhD
Time: 12:45–1 pm
Abstract
396 / 22 – Role of PHF8 in resistance to melanoma targeted therapies
Senior Author: Eva Hernando-Monge, PhD
Time: 1:30–5 pm
Monday, April 17
Session
Telehealth Research and Innovation for Veterans with Cancer (THRIVE)
Presenter: Scott E. Sherman, MD
Time: 2:58–3:06 pm
Abstract
1794 / 28 – Targeting mammalian SWI/SNF chromatin remodeling complexes to improve T cell-based cancer immunotherapies
Lead Author: Elena Battistello, PhD
Time: 9 am–12:30 pm
Abstract
2283 / 30 – An immunosuppressive ectoenzyme-expressing T cell population is associated with non-responsiveness to immune checkpoint blockade in metastatic melanoma patients
Lead Author: Ankita Mitra, PhD
Time: 9 am–12:30 pm
Abstract
CT052 / 10 – A phase 1/2 randomized study of imvotamab monotherapy and in combinationwith loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
Lead Author: Catherine S. Diefenbach, MD
Time: 9 am–12:30 pm
Abstract
SY26-01 – Mapping cellular plasticity in tumor progression and drug resistance
Presenter: Itai Yanai, PhD
Time: 10:45–11:05 am
Abstract
2819 / 10 – Genome-wide CRISPR screen identifies NANP as a radio-sensitizing target of GBM by regulating NF-κB pathway
Senior Author: Erik P. Sulman, MD, PhD
Time: 1:30–5 pm
Abstract
CT028 – A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Senior Author: Joshua K. Sabari, MD
Time: 2:35–2:45 pm
Abstract
3511 – Melanoma-shed, lymph-borne CSPG4 conditions the pre-metastatic lymph node niche
Lead Author: Haley duBois
Senior Author: Amanda W. Lund, PhD
Time: 2:37–2:52 pm
Tuesday, April 18
Symposium
SY17 – The Duplicitous Tumor Microenvironment
Chair: Amanda W. Lund, PhD
Time: 12:30–2 pm
Symposium
MS.ET01.01 – New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Chair: Janice Mehnert, MD
Time: 2:30–4:30 pm
Session
Health equity approaches to cancer prevention and control
Presenter: Chau Trinh-Shevrin, DrPH
Time: 7–7:45 am
Wednesday, April 19
Late Breaker
LB291 / 4 – Uncovering gene fusions with 3D genomics: from clinical validation to actionable insights for undiagnosable solid tumors
Senior Author: Matija Snuderl, MD
Time: 9 am–12:30 pm
Late Breaker
LB354 / 22 – 9p arm loss is an important predictor of immune evasion in several human cancers
Author: Joy Bianchi, PhD
Time: 9 am–12:30 pm
